ArticleInternational journal of antimicrobial agents2025
Pharmacodynamic insights to support pneumonia treatment in a patient co-infected with two carbapenem-resistant bacteria.
Article in International journal of antimicrobial agents, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Identifying optimal antibiotic therapy for patients infected with extensively resistant bacteria is challenging, particularly when there are multiple organisms at the infection site. Personalized time-kill assays (TKAs) can be used to test the pharmacodynamic activity of clinically relevant antibiotic combinations to help select appropriate therapy for these difficult-to-treat infections. We report a case of ventilator-associated pneumonia due to Pseudomonas aeruginosa and Providencia stuartii that were each carbapenem resistant. Due to the complex resistance phenotypes, the isolates were analysed via TKAs during the patient's hospitalization to evaluate the activity of relevant antibiotic combinations. Using the patient's isolates, the TKAs showed that a combination of ceftazidime/avibactam and a polymyxin was synergistic against the P. aeruginosa whereas ceftazidime/avibactam plus aztreonam was slightly more active than ceftazidime/avibactam alone against the P. stuartii. The results of the TKAs helped to validate the patient's treatment regimen of aztreonam, ceftazidime/avibactam, and colistin (inhaled), which successfully treated the infection. Whole genome sequencing later revealed that the P. stuartii harbored a bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.